BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/17/2016 8:44:00 AM | Browse: 266 | Download: 325
Publication Name World Journal of Hepatology
Manuscript ID 26921
Country of Manuscript Source China
Received
2016-04-29 15:31
Peer-Review Started
2016-05-04 13:54
To Make the First Decision
2016-07-04 16:49
Return for Revision
2016-07-05 10:37
Revised
2016-07-06 10:48
Second Decision
2016-07-21 17:20
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2016-08-01 15:30
Articles In Press
2016-08-01 15:30
Publication Fee Transferred
Edit the Manuscript by Languag Editor
Typeset the Manuscript
2016-08-09 10:02
Publish the Manuscript Online
2016-08-17 08:44
ISSN 1948-5182 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Gastroenterology and Hepatology
Manuscript Type Editorial
Article Title Adjuvant sorafenib in hepatocellular carcinoma: A cautionary comment of STORM trial
Manuscript Source Unsolicited Manuscript
All Author List Jian-Hong Zhong, Xue-Ke Du, Bang-De Xiang and Le-Qun Li
Funding Agency and Grant Number
Funding Agency Grant Number
Guangxi Science and Technology Development Projects 14124003-4
Guangxi University of Science and Techno­logy Research Projects KY2015LX056
the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province Z2015621
the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province Z2015601
the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province GZZC15-34
the Self-Raised Scientific Research Fund of the Ministry of Health of Guangxi Province Z2014241
the Innovation Project of Guangxi Graduate Education YCBZ2015030
Correspondence To Le-Qun Li, MD, Department of Hepato­biliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, He Di Rd #71, Nanning 530021, Guangxi Zhuang Autonomous Region, China. xitongpingjia@163.com
Keywords Adjuvant; Hepatocellular carcinoma; Tumor recurrence; Sorafenib
Core Tip Sorafenib is effective for advanced hepato-cellular carcinoma (HCC). However, its positive role as adjuvant therapy for HCC after surgery or transarterial chemoembolization is controversy.
Publish Date 2016-08-17 08:44
Citation Zhong JH, Du XK, Xiang BD, Li LQ. Adjuvant sorafenib in hepatocellular carcinoma: a cautionary comment of STORM trial. World J Hepatol 2016; 8(23): 957-960
Url http://www.wjgnet.com/1948-5182/full/v8/i23/957.htm
DOI http://dx.doi.org/10.4254/wjh.v8.i23.957
Full Article (PDF) WJH-8-957.pdf
Full Article (Word) WJH-8-957.doc
Revised Manuscript 26921-Review.docx
Peer-review Report 26921-Peer-review(s).pdf
Answering Reviewers 26921-Answering reviewers.pdf
Scientific Misconduct Check 26921-Scientific misconduct check.pdf
Scientific Editor Work List 26921-Scientific editor work list.pdf
Audio 26921-Audio core tip.mp3
Conflict-of-Interest Statement 26921-Conflict-of-interest statement.pdf
Copyright Assignment 26921-Copyright assignment.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s) 26921-Grant application form(s).pdf
Non-Native Speakers of English 26921-Language certificate.pdf